Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Novo Nordisk A/S R&D Investor Call Transcript

Jun 28, 2021 / 02:00PM GMT
Release Date Price: kr259.45 (+1.55%)
Operator

Hello, and welcome to the Novo Nordisk A/S R&D Investor Call. (Operator Instructions) I'll now hand the floor to our speakers, please begin your meeting.

Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

Thank you. Welcome to the Novo Nordisk Investor Call in connection with ADA. My name is Karsten Knudsen, CFO of Novo Nordisk. And with me today, I have Marcus Schindler, Chief Scientific Officer and EVP of Research and Early Development; as well as Martin Lange, EVP of Global Development. At today's call, there may be forward-looking statements and projections around the future, which by their very nature, clearly, inherently are uncertain and where outcomes may turn out differently.

As usual, we anchor our communications around our strategic aspirations 2025, which are covering our strategy execution as a company. Today's focus is purely on the quadrant denoted innovation and therapeutic focus, where we'll be covering our progress within raising the innovation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot